- Department for International Development
- Document Type:
- Conference Paper
- Don, R., Nare, B., Beaudet, B., Chen, D., Freund, Y. Gaukel, E., Jenks, M., Noe, A., Parham, R., Rewerts, C., Yarlett, N., Wring, S., Bacchi, C., Bowling, T., Jarnagin, K., Mercer, L., Orr, M., Plattner, J., Sligar, J., and Jacobs, R.
SCYX-6759, the first member of a new class of anti-trypanosomal drugs, was discovered by a collaboration of DNDi, Anacor, PACE University and Scynexis. It was found that it achieved 100% efficacy in a murine stage 2 human African trypanosiomiasis (HAT) model (using Trypanosoma brucei), that it readily crossed the blood-brain and blood-testicular barriers, and that its efficacy could be predicted from brain exposure. Research on SCYX-6759 led to the development of SCYX-7158, a pre-clinical candidate for HAT treatment.
Presentation from American Society of Tropical Medicine and Hygiene 58th Annual Meeting, Washington, DC, USA, 18-22 November 2009.
SCYX-6759, an Orally Bioavailable Oxaborole 6-carboxamide, Achieves Therapeutically Relevant Exposure in Brain and CSF Leading to 100% Cures in a Mouse Model of CNS-stage Human African Trypanosomiasis.
Document Type: Conference Paper
Authors: Don, R. Nare, B. Beaudet, B. Chen, D. Freund, Y. Gaukel, E. Jenks, M. Noe, A. Parham, R. Rewerts, C. Yarlett, N. Wring, S. Bacchi, C. Bowling, T. Jarnagin, K. Mercer, L. Orr, M. Plattner, J. Sligar, J. Jacobs, R.